Do-it-yourself brain hacking has moved from fringe experimentation to a cultural and clinical phenomenon, reshaping how individuals interact with their brains. Early self-directed use of nootropics, at-home brain stimulation, and meditation apps has evolved into regulated interventions, including FDA-cleared prescription digital therapeutics for ADHD, depression, and migraine. Informal mood tracking and journaling practices have informed structured cognitive behavioral therapy apps and biosensor-based adaptive interventions. The editorial traces this trajectory across three phases—experimental enthusiasts, consumer biohackers, and clinical convergence—and argues that medicine must shift from skepticism to stewardship, guiding this transformation with evidence and ethics to safeguard patient autonomy, efficacy, and safety.
A systematic review of six studies involving 12,731 participants examined digitally enabled psychedelic-assisted therapy delivered outside clinical settings, mostly at-home ketamine or esketamine supported by telehealth or mobile apps. Digital tools enabled high response rates for depression (56.4% to 62.8%) and rapid symptom improvement, particularly for depression and anxiety. Remote monitoring was feasible and acceptable, but serious safety concerns emerged, including psychiatric adverse events and one unintentional overdose, highlighting the need for strict oversight. One study on virtual ayahuasca rituals noted sociocultural potential and limitations. The field lacks controlled trials and has moderate to serious risk of bias across non-randomized studies, limiting confidence in findings.